Research & Development News summary
Phosphodiesterase-4 inhibitor
shows benefits in chronic pulmonary disease Cilomilast, a new
orally active, selective inhibitor of phosphodiesterase-4, might provide
therapeutic benefit to patients with chronic obstructive pulmonary disease,
say researchers...[more]
Promising data for asthma drug, but launch delayed
A trial has shown promising results for the new asthma drug
omalizumab but the United States Food and Drug Administration has delayed
the drug’s approval, asking for more information as it is a new chemical
entity. European regulatory authorities are likely to follow suit...[more]
Anticoagulant does not need monitoring Ximelagatran
(Exanta), a direct thrombin inhibitor, is as effective as warfarin as
prophylaxis against venous thromboembolism (VTE) and does not require
routine coagulation monitoring or dose adjustment...[more]
Recombinant protein an effective and sustained
treatment for psoriasis A recombinant protein, alefacept, is
an effective treatment for chronic plaque psoriasis, according to a new
study. It is also well tolerated and non-immunogenic...[more]
Hormone from adipose tissue could provide treatment
for type 2 diabetes Replenishing adiponectin, a hormone released
from adipose tissue, might provide a novel treatment strategy for insulin
resistance and type 2 diabetes, according to Japanese researchers...[more]
New drugs suppress menstruation safely Two
new antiprogestogens have been found to suppress menstruation safely in
animal studies...[more]
Have pharmacists found a cancer cure? Pharmacists
from De Montfort University in Leicester think they might have discovered
a cure for cancer...[more]
|
